Jump to:

AgLabs hero image

AgLabs

Follow

Argento Labs: UK biotech with the aim to convert waste to value. Innovating for a sustainable future!

0%
 - 
Funded 28 Dec 2023
£390,002 target
£415,233 from 0 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website www.aglabs.co.uk
Sectors Energy Mixed Digital/Non-Digital B2B
Company number 14492170
Incorporation date 18 Nov 2022
More
Less

Investment summary

Type Equity
Valuation (pre-money) £4.5M
Equity offered 7.98%
Tax relief

EIS

More
Less

Business highlights

  • Patented* Bioprocessing: Our advantage!
  • Eco-friendly biomaterials for a green future
  • From Waste to Wealth: High-Value Biotech Solutions
  • Opportunity in a $775 billion Bio-tech market!
More
Less

Key features

  • Secondary Market
  • Nominee investment min. £13.50 +
  • Direct investment min. £20,000.00 +

Idea

Introduction

At Argento Labs, we aim to lead the biotech revolution by transforming any agricultural, forestry, and municipal waste into valuable resources.

Our patented* bioprocessing technology extracts essential elements like sugars, proteins, and fats. We aim to address waste management to foster a circular economy, employing natural solutions, automation, machine learning, and synthetic biology for utmost efficiency and sustainability.

Our product range includes alternative proteins, biogenic CO2, and bio-fertilizers, actively reducing environmental impact and supporting decarbonization efforts. Emphasizing scalability, we strive to scale up industrial production for a sustainable future.

At Argento Labs, we envision waste becoming something magical as we work towards preserving our planet for generations to come!

*Our patent currently covers the US jurisdiction.

Substantial accomplishments to date

At Argento Labs, we take pride in securing a patent and successfully demonstrating our pretreatment process in Spain with feedstocks like rice husk and sugar cane bagasse.

We believe our distinctive advantage will be to convert agricultural waste, forestry & municipal waste into valuable biotech products with efficiency, surpassing traditional methods.

Validated by independent third-party entities, our technology excels in cost and time efficiency.

Notably, we've secured agreements in principle with clients, including a major Thai rice exporter, with plans to extract valuable sugars from rice husk for various industries.

Our bioprocessing approach efficiently converts lignocellulosic biomass and agricultural waste into valuable biotech products, offering a renewable and clean alternative to conventional processes.

Extensive research and pilot-scale testing have validated our technology's viability, paving the way for commercialisation. As we actively pursue partnerships and scale up, we aim to bring our sustainable solutions to a larger market!

Monetisation strategy

Ag Labs aims to capture 0.5% of the $775B global biotech market, setting a base target of $3.9B.

At Argento Labs, we plan to generate revenue through two primary channels: bio-prospecting research and development and turnkey bio-processing solutions.

In the bio-prospecting domain, we will employ a value-based pricing strategy, assessing the value our technology delivers compared to existing solutions. We plan to offer different licensing options, each priced according to perceived value, and we base our pricing on thorough market assessments, including market size and customer estimations.

In the realm of turnkey bio-processing solutions, we plan to provide complete systems for converting biomass into biotech products, earning revenue through sales. We aim for these dual strategies to enable us to monetize our proprietary technology and bioprocessing solutions effectively.

Services rendered in Bio-prospecting research & development:

- Compare technology value to existing solutions.
- Assess potential market size & share.
- Define licensing options based on access & support levels.
- Set pricing per license.
- Estimate potential customers for each option.
- Calculate revenue by multiplying price per license by estimated customers for each option.

We believe in prioritizing continuous R&D to improve our technology and explore new applications.

With an eye on market demand, we plan to set competitive pricing, enticing potential customers to adopt our innovative solutions.

With the aim of focusing on strategic partnerships and effective marketing, intend to make a significant impact on the biotech industry.

Use of proceeds

In terms of fund allocation, we have outlined the following budget:

40% dedicated to establishing a state-of-the-art research and development facility in the UK.

This facility will enable us to conduct extensive tests on our proprietary strains, reducing reliance on external laboratories and accelerating our development process.

Additionally, 45% has been allocated for operational expenses, office facilities, and administration, to focus on growth and market penetration.

Lastly, 15% will cover essential legal fees associated with robust IP protection, patents in new markets, and managing future patents.

These strategic investments will significantly bolster our capabilities, streamline operations, and enhance our position in the biotech market.

Key Information

Intellectual Property

The Patent for the technology is currently in the name of Richard Giles (inventor) who is the founder of Argento Labs, and this patent covers the US jurisdiction. Argento Labs have previously been licensed the patent under a Master Licensing Agreement which grants them the exclusive rights.

Richard Giles is to transfer the patent to Argento Labs Ltd, which is currently in progress. This transfer will take place before we complete this investment.

Founder Interests

Richard Giles is also a founder of Stealth BB LLC , which is a virtual consulting company incorporated in the US. He spends one hour per week on Stealth BB LLC, and is otherwise full time on Argento Labs.

Augustin Llamas and Anthony Efionayi (Co-Founders of Argento Labs) are Full Time with Argento Labs.

Open an account to get access to the team members of AgLabs

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account to get access to the AgLabs campaign updates

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account to get access to the list of investors in the AgLabs campaign

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account and verify your identity to get access to the AgLabs discussion

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account and verify your identity to get access to the AgLabs pitch deck and other documents

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This webpage has been approved as a financial promotion by Seedrs Limited (trading as Republic Europe) ("Republic Europe"), which is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. The summary information provided about investment opportunities on this webpage is intended solely to demonstrate the types of investments available on the Republic Europe platform, and any investment decision should be made on the basis of the full campaign. Full campaigns are available to investors who have become authorised to invest on the Republic Europe platform. All investment activities take place within the United Kingdom, and any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £4,500,000

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Nominee investment

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Nominee investment.

Find out more

Custodian

If you invest in this Campaign, Seedrs will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Seedrs will not benefit from any rights under a shareholder agreement. As a result, Seedrs will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

This is an option to invest and hold shares 'directly' in the company (rather than via the Nominee investment). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Seedrs. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Security Token

A security token is a digital asset that represents ownership or other rights. It is a digital form of traditional investments. In the future, you may be able to trade your investment through compatible exchanges.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel